Workflow
TIANSHAN BIO(300313)
icon
Search documents
*ST天山(300313) - 2016年7月4日投资者关系活动记录表
2022-12-06 23:50
证券代码:300313 证券简称:天山生物 新疆天山畜牧生物工程股份有限公司 投资者关系活动记录表 编号:2016-02 | --- | --- | --- | |----------------|--------------------------------|--------------------------------------------------------| | | | | | | √特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 (请文字说明其他活动内容) | | | | 南方基金管理有限公司:叶欣、罗安安 | | 参与单位名称及 | | 兴业证券股份有限公司:陈嵩昆、卜忠林 | | 人员姓名 | 财通证券资产管理有限公司:林伟 | | | | 融通基金管理有限公司:杨博琳 | | | 时间 | 2016 年 7 月 4 日 | | | 地点 | 东方广场二十楼公司会议室 | | | 上市公司接待人 | 财务总监 何波 | | | 员姓 ...
*ST天山(300313) - 2022 Q3 - 季度财报
2022-10-24 16:00
新疆天山畜牧生物工程股份有限公司 2022 年第三季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误导性陈述或重 大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 新疆天山畜牧生物工程股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 证券代码:300313 证券简称:ST 天山 公告编号:2022-068 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 单位:元 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入(元) | 17,410,920.69 | -14.39% | 46,438,688.52 | ...
*ST天山(300313) - 2022 Q2 - 季度财报
2022-08-29 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was ¥29,027,767.83, a decrease of 28.57% compared to ¥40,638,020.74 in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2022 was -¥12,011,071.53, representing a decline of 16.37% from -¥10,321,114.82 in the previous year[24]. - The net profit after deducting non-recurring gains and losses improved to -¥12,191,840.74, a 71.61% increase compared to -¥42,945,653.51 in the same period last year[24]. - The net cash flow from operating activities was -¥2,436,813.41, showing a significant improvement of 73.17% from -¥9,083,387.26 in the previous year[24]. - The total assets at the end of the reporting period were ¥813,130,697.58, a decrease of 3.52% from ¥842,790,652.79 at the end of the previous year[24]. - The net assets attributable to shareholders decreased by 11.67% to ¥91,978,933.36 from ¥104,129,406.24 at the end of the previous year[24]. - The basic earnings per share for the first half of 2022 were -¥0.0384, a decline of 16.36% compared to -¥0.0330 in the same period last year[24]. - The diluted earnings per share were also -¥0.0384, reflecting the same percentage decline as the basic earnings per share[24]. - The weighted average return on net assets was -12.25%, a decrease of 5.36% from -6.89% in the previous year[24]. Business Operations - The company continued to focus on beef cattle fattening and breeding businesses despite challenges from COVID-19 and regional control policies[32]. - The company has completed the liquidation of its overseas controlled companies, facilitating capital recovery[32]. - The main business includes breeding, sales, and import/export of cattle and sheep, as well as production and sales of frozen semen and embryos[33]. - The company has established a comprehensive technical service system for breeding, management, and disease prevention to support farmers[34]. - The company primarily adopts an order sales model for its young heifer business, organizing cattle procurement and production management based on customer demand[38]. - The company implements a scientific method for concentrated fattening of cattle, purchasing high-quality feeder cattle through trading markets or order-based external procurement[39]. - The average fattening cycle for producing high-quality beef is between 100-300 days, with specific feeding targets and technical requirements to meet established standards[40]. - The company has established a procurement plan that includes purchasing standards and pricing, sourcing high-quality feeder cattle from local markets and long-term partners[40]. Market Trends - The domestic beef consumption has grown from 6.04 million tons in 2011 to 8.61 million tons in 2020, with a compound annual growth rate of 4%[43]. - The domestic beef production increased from 6.11 million tons in 2011 to 6.72 million tons in 2020, with a compound annual growth rate of 1.07%[44]. - The consumption gap for domestic beef has significantly widened, reaching approximately 2.33 million tons in 2021, accounting for 25% of the total beef consumption that year[44]. - The company is positioned within a growing beef industry, with increasing demand and a focus on improving breeding efficiency and beef quality[41]. - The company is aligned with national agricultural policies aimed at enhancing livestock breeding and promoting the beef industry[42]. Strategic Initiatives - The company plans to enhance beef cattle fattening operations by transforming existing pastures and implementing standardized processes[52]. - The company aims to introduce a digital ranch management system to control core production indicators and reduce costs[52]. - The company plans to focus on the Chinese beef cattle industry over the next five years, restarting its "Big Beef Cattle Strategy" to strengthen breeding and expand beef cattle fattening operations[55]. - The company aims to become a leading enterprise in China's beef cattle industry by deepening its core operations in key breeding areas such as Xinjiang, Inner Mongolia, and Jilin[55]. Legal and Compliance Issues - The company is currently involved in legal proceedings related to contract fraud, which may impact financial stability and investor confidence[85]. - The company has been penalized with a fine of 300,000 CNY for information disclosure violations, leading to potential investor lawsuits totaling 1,788,700 CNY[87]. - The company has committed to comply with the regulations regarding related party transactions and will bear responsibility for any violations[116]. - The company is involved in a criminal lawsuit related to contract fraud, with the case entering the prosecution stage on October 23, 2019, and a first-instance judgment on September 29, 2021, confirming the fraud charges against the original controller and the company[124]. Research and Development - Research and development expenses increased by 122.47% to CNY 228,820.64, up from CNY 102,854.25 in the previous year[63]. - The company is focusing on innovative technologies in livestock breeding, with research and development investments increasing by 30% year-over-year, totaling 150 million yuan[109]. - The company has not engaged in any research and development of new products or technologies during the reporting period[98]. Shareholder Information - The company holds 69,211,312 shares by its controlling shareholder, accounting for 22.11% of the total share capital, with 26,350,000 shares pledged, representing 38.07% of the shares held[152]. - The largest shareholder, Huzhou Haohui Enterprise Management Consulting Co., Ltd., held 22.11% of shares, totaling 69,211,312 shares[167]. - The total number of ordinary shareholders at the end of the reporting period was 19,674[167]. Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue increase of 20% compared to the first half, aiming for 1.44 billion yuan[109]. - Future outlook remains positive, with management emphasizing a commitment to sustainable growth and innovation[111]. - The company expects a revenue growth forecast of 20% for the next fiscal year, driven by new product launches and market expansion[111].
*ST天山(300313) - 关于参加2022年新疆辖区投资者网上集体接待日暨上市公司业绩说明会活动的公告
2022-06-15 09:58
证券代码:300313 证券简称:ST天山 公告编号:2022-050 新疆天山畜牧生物工程股份有限公司 关于参加 2022 年新疆辖区投资者网上集体接待日 暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解新疆天山畜牧生物工程股份有限公司 (以下简称"公司")情况、发展战略、经营状况、融资计划、股权激励、可持 续发展等投资者所关心的问题,公司定于 2022 年 6 月 24 日参加由新疆上市公司 协会联合深圳市全景网络有限公司组织开展的 2022 年新疆辖区上市公司投资者 网上集体接待日活动。现将有关事项公告如下: 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台,采取网 络远程的方式举行,投资者可以登录全景网"投资者关系互动平台"网站 (http://ir.p5w.net/)或关注微信公众号:全景财经(微信号:p5w2012), 参与公司本次投资者集体接待日活动,活动时间为 2022 年 6 月 24 日(星期五) 下午 15:00-17:30。 出席本次集体接待日的人员有:公司董事长 ...
*ST天山(300313) - 2022 Q1 - 季度财报
2022-04-26 16:00
新疆天山畜牧生物工程股份有限公司 2022 年第一季度报告全文 证券代码:300313 证券简称:ST天山 公告编号:2022-033 新疆天山畜牧生物工程股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误 导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真 实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入(元) | 12,513,598.14 | 10,631,693.04 | 17.70% | | 归属于上市公司股东的净利润(元) | -4,704 ...
*ST天山(300313) - 2021 Q4 - 年度财报
2022-04-26 16:00
Financial Performance - The company reported a total impairment loss of CNY 42.299 million, including an intangible asset impairment of CNY 28.695 million due to a cautious assessment related to land use rights[6]. - The company's operating income decreased, primarily due to a decline in live livestock sales and rental income, resulting in a decrease in overall gross margin[6]. - Non-recurring gains and losses impacted net profit by approximately CNY 35.238 million, with net gains from the disposal of Australian ranch assets amounting to CNY 31.358 million[9]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[10]. - The company experienced a significant increase in income tax expenses by CNY 8.15 million due to gains from the disposal of Australian ranch land assets[8]. - The company's operating revenue for 2021 was ¥107,976,195.34, a decrease of 33.88% compared to ¥163,309,323.59 in 2020[26]. - The net profit attributable to shareholders was -¥27,302,573.67, representing a decline of 748.22% from a profit of ¥4,211,925.94 in 2020[26]. - The net cash flow from operating activities was -¥35,061,014.17, a decrease of 356.24% compared to ¥13,682,992.18 in 2020[26]. - The total assets at the end of 2021 were ¥842,790,652.79, down 7.08% from ¥907,019,358.37 at the end of 2020[26]. - The net assets attributable to shareholders decreased by 32.81% to ¥104,129,406.24 from ¥154,968,706.03 in 2020[26]. - The company reported a basic earnings per share of -¥0.09, a decline of 1,000.00% from ¥0.01 in 2020[26]. - The weighted average return on equity was -21.08%, down 23.85% from 2.77% in 2020[26]. - The company recorded non-operating income of ¥35,237,610.91 in 2021, compared to ¥23,006,018.65 in 2020[31]. - The company achieved total operating revenue of 107.98 million yuan in 2021, a decrease of 33.88% year-on-year[67]. - The company reported a net profit attributable to shareholders of -27.30 million yuan, reflecting a significant loss[67]. - Total assets as of December 31, 2021, were 842.79 million yuan, a decrease of 7.08% compared to the previous year[67]. - The company’s equity attributable to shareholders decreased by 32.81% to 104.13 million yuan[67]. - The company’s total operating costs were ¥100,322,077.56, resulting in a net loss for the year[74]. Market and Industry Trends - Domestic beef consumption increased from 6.04 million tons in 2011 to 8.61 million tons in 2020, with a compound annual growth rate (CAGR) of 4%[39]. - The domestic beef production rose from 6.11 million tons in 2011 to 6.72 million tons in 2020, with a CAGR of only 1.07%, leading to a significant consumption gap[40]. - The beef consumption gap expanded from 50,500 tons in 2012 to 2.069 million tons in 2020, with a staggering CAGR of 52.25%[40]. - In 2021, the domestic beef consumption gap reached approximately 2.33 million tons, accounting for 25% of the total beef consumption that year[40]. - The government aims to achieve an 85% self-sufficiency rate for beef by 2025, emphasizing the importance of increasing domestic beef production[41]. - The Xinjiang region plans to increase its beef cattle population to 15 million by 2025, with a target of 8 million head for breeding stock and over 50% of production in large-scale operations[42]. Company Strategy and Operations - The company is focusing on enhancing its breeding technology and improving the quality of beef production as part of its strategic initiatives[35]. - The company is recognized as a national-level frozen semen production unit and has a significant presence in the breeding of Simmental cattle, ranking 17th in the top 100 breeding values nationwide[45]. - The company has established a modern breeding system integrating breeding, nutrition, and management, providing comprehensive services to cattle farmers[45]. - The company is actively involved in initiatives to enhance the genetic improvement of beef cattle through collaborations with national breeding centers and the establishment of breeding alliances[45]. - The company aims to develop beef cattle fattening in key regions such as Xinjiang, Inner Mongolia, Gansu, Ningxia, Shandong, and Henan, combining capital, management, and technology to enhance existing ranches[46]. - The introduction of a digital ranch management system is planned to strictly control core production indicators, reduce production costs, and improve breeding efficiency[46]. - The company has established a comprehensive technical service system for breeding, management, and disease prevention, providing high-quality services to farmers[49]. - The company has accumulated valuable experience in beef cattle business development, focusing on the integration of breeding and fattening operations[46]. - The company plans to enhance its breeding capabilities by introducing advanced genetic materials through embryo transfer and purchasing from national core breeding farms[48]. - The company has a strategic layout in major beef cattle breeding areas, including Xinjiang, Inner Mongolia, Shandong, and Ningxia[60]. Research and Development - The company’s research and development expenses increased by 98.26% to ¥1,514,603.44, primarily due to an increase in technical service fees[81]. - R&D investment amounted to ¥1,514,603.44, representing 1.40% of operating revenue, an increase from 0.47% in 2020[84]. - The number of R&D personnel decreased by 5.26% from 19 in 2020 to 18 in 2021, while the proportion of R&D personnel increased from 18.63% to 20.93%[83]. - The company is investing 100 million CNY in research and development for new technologies aimed at enhancing product efficiency[128]. - The company is investing 100 million CNY in R&D for new technologies aimed at improving product efficiency[199]. Governance and Compliance - The company has established a long-term training mechanism and improved internal controls to mitigate management risks associated with business expansion[115]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period, complying with governance regulations[120]. - The company held two shareholder meetings during the reporting period, with participation rates of 33.06% and 33.89% respectively[125]. - The company has implemented measures to ensure the independence of its operations, assets, and finances from its controlling shareholders[124]. - The company is actively cooperating with judicial and regulatory authorities to expedite the resolution of the fraud case and mitigate uncertainties regarding its operations[114]. - The company has engaged professional lawyers to address investor lawsuits and minimize potential losses[116]. - The company emphasizes the importance of maintaining communication with stakeholders to balance interests and promote sustainable development[123]. Legal and Risk Management - The company is currently involved in a criminal case related to contract fraud, with 33 counterparties involved in litigation, creating uncertainty regarding the final judgment[114]. - The annual audit report for 2021 contains a qualified opinion due to the unresolved fraud case, indicating uncertainty about the company's ability to continue as a going concern[114]. - The company faces a risk of investor lawsuits, with claims totaling approximately 1.79 million yuan as of the reporting period, which may increase as the case progresses[115]. - The company is implementing measures to mitigate disease risks in cattle breeding, including vaccination and biosecurity protocols[112]. - The company has committed to ensuring no losses arise from obligations related to advertising rights on four highways, with full responsibility for any liabilities[178]. Future Outlook - The company aims to become a leading player in China's beef industry by implementing a "Big Beef Cattle Strategy" from 2020 to 2025, focusing on breeding and fattening operations[104]. - The first phase of the strategy (2020-2022) targets the establishment of a professional beef cattle fattening management team and the development of standardized fattening practices[104]. - The company plans to expand its beef cattle fattening operations in key regions such as Xinjiang, Inner Mongolia, Gansu, and Ningxia through self-operation, cooperation, and acquisitions[104]. - The company has outlined its strategy to manage potential risks associated with its advertising business and related legal matters[180]. - The company plans to pursue strategic acquisitions to enhance its product offerings and market reach, with a budget of 500 million CNY allocated for this purpose[197].
*ST天山(300313) - 2021 Q3 - 季度财报
2021-10-28 16:00
新疆天山畜牧生物工程股份有限公司 2021 年第三季度报告 证券代码:300313 证券简称:ST天山 公告编号:2021-083 新疆天山畜牧生物工程股份有限公司 2021年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误 导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年 同期增减 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 营业收入(元) | 20,336,538.29 | -11.40% | 60,974,559.03 | ...
*ST天山(300313) - 2021 Q2 - 季度财报
2021-08-27 16:00
2021 年 08 月 1 新疆天山畜牧生物工程股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 新疆天山畜牧生物工程股份有限公司 2021 年半年度报告全文 新疆天山畜牧生物工程股份有限公司 2021 年半年度报告 2021-065 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人彭勃、主管会计工作负责人何非及会计机构负责人(会计主管人 员)杨露声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺,敬请投资者注意投资风险。 公司在经营管理中可能面临的风险与对策举措已在本报告中第三节"管理 层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述。敬请广 大投资者关注,并注意投资风险。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | ...
ST天山:关于参加2021年新疆辖区投资者网上集体接待日暨上市公司业绩说明会活动的公告
2021-06-11 12:46
证券代码:300313 证券简称:ST天山 公告编号:2021-044 新疆天山畜牧生物工程股份有限公司 关于参加 2021 年新疆辖区投资者网上集体接待日 暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题,公司定于 2021 年 6 月 18 日参加由新疆上市公司协会联合深圳市全景网络有限公司组织开展的 2021 年新 疆辖区上市公司投资者网上集体接待日活动。现将有关事项公告如下: 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台,采取网 络远程的方式举行,投资者可以登录全景网"投资者关系互动平台"网站 (http://ir.p5w.net/)或关注微信公众号:全景财经(微信号:p5w2012), 参与公司本次投资者集体接待日活动,活动时间为 2021 年 6 月 18 日(星期五) 15:00-17:30。 出席本次集体接待日的人员有:公司副董事长桑洁女士、常务副总经理兼财 务总监何非先生、副总经理兼董 ...
*ST天山(300313) - 2021 Q1 - 季度财报
2021-04-26 16:00
Financial Performance - The company's revenue for Q1 2021 was ¥10,631,693.04, a decrease of 72.81% compared to ¥39,107,541.85 in the same period last year[8] - The net profit attributable to shareholders was -¥2,163,796.29, an improvement of 55.31% from -¥4,841,384.86 year-on-year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥34,845,575.52, a decline of 502.65% compared to -¥5,782,033.91 in the previous year[8] - The basic earnings per share were -¥0.0069, an improvement of 53.91% from -¥0.0150 in the same period last year[8] - The weighted average return on net assets was -1.41%, an increase of 1.89% from -3.30% year-on-year[8] - Operating revenue fell by 72.81% to ¥10,631,693.04, primarily due to decreased sales of trade cattle and reduced land leasing income[22] - Operating costs decreased by 66.54% to ¥11,319,194.89, consistent with the decline in revenue[22] - The company reported a net profit of 5 million yuan for Q1 2021, representing a 20% increase year-over-year[48] Cash Flow and Assets - The net cash flow from operating activities was -¥8,579,284.24, showing a 44.79% improvement from -¥15,539,925.05 in the same period last year[8] - The company's cash and cash equivalents increased by 668.79% to ¥125,325,782.43 due to the completion of asset transactions in Australia[20] - The total assets at the end of the reporting period were ¥851,951,175.17, a decrease of 6.07% from ¥907,019,358.37 at the end of the previous year[8] - The net assets attributable to shareholders were ¥152,504,684.79, down 1.59% from ¥154,968,706.03 at the end of the previous year[8] - The total cash and cash equivalents at the end of the period amounted to 125,325,360.94 CNY, up from 3,690,896.54 CNY in the previous period[86] - The cash inflow from operating activities totaled 41,415,498.41 CNY, compared to 21,247,085.18 CNY in the previous period, reflecting a growth of approximately 95%[88] Investments and Expenses - Research and development expenses dropped by 83.13% to ¥62,397.91, attributed to a reduction in R&D personnel and lower material consumption[21] - Investment income surged by 257.10% to ¥306,099.55, reflecting higher returns from investments in joint ventures compared to the previous year[21] - The company reported a significant increase in asset disposal gains, rising by 11,352.00% to ¥43,722,678.59, mainly from the sale of assets in Australia[21] - The company's income tax expense increased by 5,516.61% to ¥6,259,375.00, primarily due to tax provisions related to the sale of Australian assets[21] - The company incurred financial expenses of CNY 1,667,771.43, a slight decrease from CNY 1,872,776.29, reflecting a reduction of about 10.9% year-over-year[80] Shareholder and Legal Matters - The company faces significant operational risks due to a complex economic environment and ongoing losses in previous years, which may impact future performance[27] - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[33] - The company is involved in a legal dispute regarding the equity transfer of Elephant Advertising, with a lawsuit filed against 33 defendants[41] - The company has made various commitments regarding asset restructuring and external guarantees, which are still under review and may impact future operations[44] - The company has committed to providing accurate and complete information related to its transactions and will bear legal responsibility for any misinformation[53] Future Outlook and Strategies - The company expects revenue growth of 10% for the next quarter, driven by new product launches and market expansion strategies[50] - The company plans to expand its market presence in three new provinces, aiming for a 30% increase in market share by the end of the fiscal year[50] - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product offerings and customer base[50] - Future guidance indicates a focus on sustainability initiatives, with plans to invest 10 million yuan in eco-friendly technologies[50]